Lenalidomide Stada Arzneimittel Ag (Lenalidomide)

Lenalidomide binds to the cereblon protein, a component of the CRL4 E3 ubiquitin ligase complex. This binding changes the complex’s activity, leading to the degradation of specific transcription factors such as Ikaros and Aiolos. The result is reduced angiogenesis, enhanced immune‑mediated tumor cell death, and inhibition of cancer cell proliferation.

The prescribed dose of Lenalidomide is individualized by the treating physician based on the specific indication, disease stage, renal function, and any concomitant therapies. Dosing regimens may differ between multiple myeloma and myelodysplastic syndromes, and adjustments are made to balance efficacy with safety.

Lenalidomide is classified as Pregnancy Category X because it is known to cause severe fetal harm. It is contraindicated in pregnancy, and effective contraception must be used by both male and female patients of reproductive potential. Breastfeeding is not recommended while on therapy due to potential drug exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory drug (IMiD) that generally offers greater potency and a more favorable safety profile than thalidomide, the first‑generation agent. Compared with pomalidomide, another newer IMiD, lenalidomide is often used earlier in treatment algorithms and may have different dosing schedules and toxicity patterns.

Lenalidomide tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Lenalidomide is taken orally as a tablet, usually once daily on a schedule defined by the prescriber. The tablet should be swallowed whole with water and can be taken with or without food, unless specific instructions are provided by the healthcare professional.

The most serious risks include the development of blood clots (deep‑vein thrombosis or pulmonary embolism), severe neutropenia that can predispose to infections, and the rare occurrence of secondary primary malignancies. Patients should be monitored regularly for signs of these events and report any concerning symptoms promptly.

Lenalidomide should not be used by individuals who are pregnant, planning to become pregnant, or not using reliable contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any of its excipients, and caution is advised in those with severe renal impairment or uncontrolled infections.